Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 384 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Renal Impaired Clear all

Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157

View directory record Official record

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older

Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Source: ClinicalTrials.gov public record

Updated Oct 14, 2024 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011

NCT02431481

View directory record Official record

Conditions: Normal Renal Function, Impaired Renal Function
Interventions: LEE011; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Source: ClinicalTrials.gov public record

Updated Dec 18, 2020 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

NCT05061979

View directory record Official record

Conditions: Contrast Enhancement in Magnetic Resonance Imaging
Interventions: BAY1747846; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Miami, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated Nov 20, 2022 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Results available

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

NCT00445302

View directory record Official record

Conditions: Renal Impairment
Interventions: plerixafor; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years

Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 3
States / cities: Santa Ana, California • Saint Paul, Minnesota • Omaha, Nebraska

Source: ClinicalTrials.gov public record

Updated Mar 12, 2014 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 3 Interventional Results available

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

NCT00634049

View directory record Official record

Conditions: Aspergillosis, Invasive Fungal Infections
Interventions: isavuconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older

Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more

Source: ClinicalTrials.gov public record

Updated Dec 10, 2024 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193

View directory record Official record

Conditions: Anemia, End Stage Renal Disease
Interventions: AKB-6548; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years

Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 16
States / cities: El Granada, California • Long Beach, California • San Dimas, California + 13 more

Source: ClinicalTrials.gov public record

Updated Jun 30, 2022 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 3 Interventional

A Study Evaluating the Pharmacokinetics, Efficacy, Safety and Tolerability of CABENUVA

NCT05601128

View directory record Official record

Conditions: HIV-1-infection, HIV Infections, HIV I Infection
Interventions: CAB + RPV; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years

Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Source: ClinicalTrials.gov public record

Updated Jun 3, 2025 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

NCT03506854

View directory record Official record

Conditions: Renal Impairment
Interventions: ISIS 681257; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years and older

Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Orlando, Florida • Knoxville, Tennessee

Source: ClinicalTrials.gov public record

Updated May 21, 2019 · Synced May 22, 2026, 12:13 AM EDT

Completed No phase listed Observational

Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment

NCT02917057

View directory record Official record

Conditions: Type 2 Diabetes
Interventions: exenatide once weekly, basal insulin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: Not listed

Enrollment: 6,024 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Source: ClinicalTrials.gov public record

Updated Mar 28, 2018 · Synced May 22, 2026, 12:13 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)

NCT07154901

View directory record Official record

Conditions: Renal Impairment
Interventions: Opemalirsen (AZD2373); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Feb 23, 2026 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

NCT01555008

View directory record Official record

Conditions: Type 2 Diabetes Mellitus, Renal Impairment
Interventions: LX4211, LX4211 Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Chula Vista, California • Edgewater, Florida + 3 more

Source: ClinicalTrials.gov public record

Updated Sep 8, 2013 · Synced May 22, 2026, 12:13 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT07348237

View directory record Official record

Conditions: Chronic Kidney Failure, End-Stage Renal Disease, Renal Impairment
Interventions: MK-2828; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 24 Years to 85 Years

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Apr 1, 2026 · Synced May 22, 2026, 12:13 AM EDT

Withdrawn Phase 4 Interventional

Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography

NCT00335101

View directory record Official record

Conditions: Coronary Artery Disease (CAD), Renal Impairment, Diabetes Mellitus
Interventions: Iodixanol, Ioversol, Iopromide; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Princeton, New Jersey

Source: ClinicalTrials.gov public record

Updated Apr 28, 2019 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

NCT05489614

View directory record Official record

Conditions: Renal Impairment
Interventions: Olpasiran; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years

Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Rialto, California • Yucaipa, California • Miami, Florida + 2 more

Source: ClinicalTrials.gov public record

Updated Nov 25, 2025 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment

NCT00863707

View directory record Official record

Conditions: Kidney Diseases, Coronary Artery Disease
Interventions: Regadenoson, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older

Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 41
States / cities: Anniston, Alabama • Little Rock, Arkansas • Bell Gardens, California + 36 more

Source: ClinicalTrials.gov public record

Updated May 17, 2012 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 4 Interventional

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

NCT02864199

View directory record Official record

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 12
States / cities: Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more

Source: ClinicalTrials.gov public record

Updated Aug 10, 2016 · Synced May 22, 2026, 12:13 AM EDT

Terminated Phase 4 Interventional Results available

A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment

NCT03226899

View directory record Official record

Conditions: Gout, Chronic Kidney Disease (CKD)
Interventions: Lesinurad, XOI, Placebo, colchicine, corticosteroids; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years

Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 70
States / cities: Birmingham, Alabama • Tucson, Arizona • Covina, California + 59 more

Source: ClinicalTrials.gov public record

Updated Nov 3, 2021 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252

View directory record Official record

Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions: Placebo, Sotagliflozin; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older

Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 51
States / cities: Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more

Source: ClinicalTrials.gov public record

Updated Jun 24, 2021 · Synced May 22, 2026, 12:13 AM EDT

Completed No phase listed Observational

Follow-up Study to Previous CARE Trial

NCT00479024

View directory record Official record

Conditions: Moderate to Severe Chronic Kidney Disease
Interventions: iodinated contrast agent; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: 18 Years and older

Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Source: ClinicalTrials.gov public record

Updated Sep 29, 2009 · Synced May 22, 2026, 12:13 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function

NCT06911320

View directory record Official record

Conditions: Healthy Volunteer Study, Hepatic Impairment, Renal Impairment
Interventions: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination; Drug
Lead sponsor: Atea Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Source: ClinicalTrials.gov public record

Updated Apr 12, 2026 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment

NCT02709382

View directory record Official record

Conditions: Renal Impairment
Interventions: Cefepime and Tazobactam combination; Drug
Lead sponsor: Wockhardt; Industry
Eligibility: 18 Years to 80 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Aug 25, 2016 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)

NCT01575925

View directory record Official record

Conditions: Multiple Myeloma, Renal Impairment
Interventions: 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older

Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: Denver, Colorado • Atlanta, Georgia • Harvey, Illinois + 4 more

Source: ClinicalTrials.gov public record

Updated Nov 3, 2022 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

NCT01309438

View directory record Official record

Conditions: Healthy, Renal Insufficiency
Interventions: Rivaroxaban (normal renal function), Rivaroxaban (mild and moderate renal impairment), Erythromycin (normal renal function), Erythromycin (mild and moderate renal function); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 35 Years to 75 Years

Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Saint Paul, Minnesota + 1 more

Source: ClinicalTrials.gov public record

Updated Oct 7, 2014 · Synced May 22, 2026, 12:13 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent Hemodialysis

NCT06723535

View directory record Official record

Conditions: Kidney Failure, Chronic, Healthy Volunteers, Renal Impairment
Interventions: BMS-986278; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 84 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida

Source: ClinicalTrials.gov public record

Updated Oct 13, 2025 · Synced May 22, 2026, 12:13 AM EDT